Linglong Yin
Overview
Explore the profile of Linglong Yin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yin L, Dai Y, Wang Y, Liu S, Ye Y, Fu Y, et al.
Oncogene
. 2025 Mar;
PMID: 40044984
Prostate cancer (PCa) is an androgen-dependent malignancy, with HSP90 and HSP70 serving as classical molecular chaperones that maintain androgen receptor (AR) protein stability and regulate its transcriptional activation. Surprisingly, our...
2.
Peng Y, Qi X, Ding L, Huang J, Liu Y, Zheng R, et al.
Br J Cancer
. 2024 Nov;
132(1):81-92.
PMID: 39582087
Background: S-phase kinase-associated protein 2 (SKP2) is a typical oncogene aberrantly overexpressing in a variety of cancer types, but it remains elusive whether SKP2 regulates the antitumor immunity of triple-negative...
3.
Peng Y, Liu Y, Zheng R, Ye Y, Fu Y, Yin L, et al.
Cell Death Discov
. 2023 Oct;
9(1):367.
PMID: 37788997
PLK1 is a key serine/threonine kinase as well as a master mitotic regulator, but it has never been reported that PLK1 regulates DNA methylation. In the present study, we for...
4.
Qi X, Liu Y, Peng Y, Fu Y, Fu Y, Yin L, et al.
J Cell Biol
. 2023 Sep;
222(11).
PMID: 37728657
UHRF1 is an epigenetic coordinator bridging DNA methylation and histone modifications. Additionally, UHRF1 regulates DNA replication and cell cycle, and its deletion induces G1/S or G2/M cell cycle arrest. The...
5.
Deng T, Xie L, Xiaofang C, Zhang Z, Xiao Y, Peng Y, et al.
Cell Oncol (Dordr)
. 2023 Sep;
47(1):245-258.
PMID: 37676377
Purpose: Platinum-based chemotherapy remains a standard-of-care for most patients with advanced non-small cell lung cancer (NSCLC). DNA damage response (DDR) induced by platinum or Etoposide activated a panel of cell...
6.
Yin L, Ye Y, Zou L, Lin J, Dai Y, Fu Y, et al.
J Exp Clin Cancer Res
. 2023 Aug;
42(1):204.
PMID: 37563661
Background: Prostate cancer(PCa) is the most commonly occurring male cancer in the USA. Abiraterone or Enzalutamide have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). However, the...
7.
Peng Y, Tang R, Ding L, Zheng R, Liu Y, Yin L, et al.
Eur J Pharmacol
. 2023 Jan;
942:175522.
PMID: 36681316
Prostate cancer (PCa) represents the second cause of cancer death in adult men. Aberrant overexpression of UHRF1 has been reported in several cancer types, and is regarded as a novel...
8.
AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer
Fu Y, Cao T, Zou X, Ye Y, Liu Y, Peng Y, et al.
Oncogenesis
. 2023 Jan;
12(1):1.
PMID: 36593255
Oncogenic activation of PI3K/AKT signaling pathway, together with epigenetic aberrations are the characters of castration-resistant prostate cancer (CRPC). UHRF1 as a key epigenetic regulator, plays a critical role in prostate...
9.
Deng T, Zhu Q, Xie L, Liu Y, Peng Y, Yin L, et al.
Mol Carcinog
. 2022 Jun;
61(8):812-824.
PMID: 35652616
Radiotherapy (RT) is a conventional cancer therapeutic modality. However, cancer cells tend to develop radioresistance after a period of treatment. Diagnostic markers and therapeutic targets for radiosensitivity are severely lacking....
10.
Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, et al.
J Exp Clin Cancer Res
. 2022 Feb;
41(1):72.
PMID: 35193658
No abstract available.